Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 with AVEO, and opening up the possibility of research in ophthalmology.
Children in England and Wales with a rare inherited disorder causing soft and weak bones can have access to a new therapy after NICE said Kyowa Kirin’s Crysvita can receive regular NHS fund